Oncology is still expanding fast, even as the human burden keeps climbing. By 2050, global cancer cases are projected to reach 35 million, while the global oncology market is forecast to hit $466.8 billion by 2032. The gap between rising demand and the pace of R and D, approvals, and trial starts is where many of the most revealing patterns show up.
Key Takeaways
- In 2022, there were 20 million new cancer cases worldwide according to GLOBOCAN estimates.
- Cancer caused 9.7 million deaths globally in 2022.
- Breast cancer incidence reached 2.3 million new cases in 2022 worldwide.
- Global cancer cases projected to rise to 35 million by 2050.
- Oncology market expected to reach $625 billion by 2030 at 8.5% CAGR.
- U.S. cancer care costs projected at $245 billion annually by 2030.
- The global oncology market was valued at $208.3 billion in 2023 and is expected to grow to $466.8 billion by 2032 at a CAGR of 9.4%.
- Oncology drugs accounted for 22% of global pharmaceutical R&D spending in 2022, totaling $58 billion.
- The U.S. oncology market size reached $89.5 billion in 2023, representing 43% of the global market.
- In 2022, FDA approved 15 new oncology drugs.
- Keytruda (pembrolizumab) generated $25 billion in sales in 2023.
- Opdivo sales reached $9.0 billion globally in 2023.
- Global oncology R&D pipeline includes 1,891 novel agents in 2023.
- Oncology clinical trials: 4,200 new starts in 2023.
- $198 billion invested in oncology R&D globally in 2022.
Cancer cases keep rising, and oncology spending is set to surge as the pipeline expands toward 2050.
Related reading
01 · Category
Cancer Incidence And Mortality30 stats
01
In 2022, there were 20 million new cancer cases worldwide according to GLOBOCAN estimates.
02
Cancer caused 9.7 million deaths globally in 2022.
03
Breast cancer incidence reached 2.3 million new cases in 2022 worldwide.
04
Lung cancer accounted for 2.5 million new cases and 1.8 million deaths in 2022.
05
Colorectal cancer incidence was 1.9 million cases globally in 2022.
06
Prostate cancer new cases totaled 1.5 million in 2022 worldwide.
07
U.S. cancer incidence rate was 442 per 100,000 in 2023 estimates.
08
Global cancer mortality rate has declined 32% since 1991 in high-income countries.
09
Stomach cancer caused 769,000 deaths in 2022 globally.
10
Liver cancer incidence 905,000 cases and 830,000 deaths in 2022.
11
Cervical cancer new cases 660,000 and 350,000 deaths in 2022.
12
In Europe, 4 million new cancer cases diagnosed in 2022.
13
U.S. cancer deaths totaled 609,820 in 2023 projections.
14
Pancreatic cancer mortality rate 12.5 per 100,000 globally in 2022.
15
Skin melanoma incidence 325,000 cases worldwide in 2022.
16
Leukemia caused 312,000 deaths in 2022 globally.
17
In low-income countries, 70% of cancer deaths occur due to late diagnosis.
18
Global 5-year cancer survival rate averages 67% in high-income nations.
19
Esophageal cancer 511,000 cases and 439,000 deaths in 2022.
20
Thyroid cancer incidence doubled to 586,000 cases from 2000-2022.
21
Non-Hodgkin lymphoma 544,000 new cases in 2022.
22
U.K. cancer incidence 375,000 cases annually on average 2017-2019.
23
Bladder cancer 614,000 cases and 273,000 deaths in 2022.
24
Brain cancer incidence 308,000 cases globally in 2022.
25
Kidney cancer 431,000 cases and 179,000 deaths in 2022.
26
Ovarian cancer 316,000 cases and 207,000 deaths in 2022.
27
Global cancer prevalence (5-year) estimated at 53.5 million in 2022.
28
U.S. age-adjusted cancer mortality rate fell to 146 per 100,000 in 2022.
29
Endometrial cancer incidence 417,000 cases in 2022.
30
Multiple myeloma 160,000 new cases worldwide in 2022.
Interpretation
Cancer Incidence And Mortality Interpretation
In the Cancer Incidence And Mortality category, 2022 saw 20 million new cancer cases worldwide alongside 9.7 million deaths, showing that nearly half of those diagnosed ultimately die, with lung cancer alone producing 2.5 million new cases and 1.8 million deaths.
02 · Category
Economic Impact And Projections28 stats
01
Global cancer cases projected to rise to 35 million by 2050.
02
Oncology market expected to reach $625 billion by 2030 at 8.5% CAGR.
03
U.S. cancer care costs projected at $245 billion annually by 2030.
04
Global spending on cancer drugs forecasted to hit $375 billion by 2027.
05
Immuno-oncology market to grow to $125 billion by 2030.
06
Precision medicine in oncology to reach $197 billion by 2030.
07
Cancer treatment costs in Europe projected €102 billion by 2025.
08
U.S. patient out-of-pocket cancer costs average $12,000per year projected to rise 20% by 2030.
09
Global biosimilars oncology savings projected $100 billion by 2030.
10
CAR-T market to expand to $25 billion by 2030 at 35% CAGR.
11
Oncology drug prices expected to increase 5-7% annually through 2028.
12
China oncology market to $70 billion by 2030.
13
Lost economic output from cancer globally $1.16 trillion annually projected to rise.
14
ADC market forecasted $26 billion by 2030.
15
U.K. cancer economic burden £17.5 billion per year by 2035 projections.
16
Global liquid biopsy market to $20 billion by 2030 in oncology.
17
Radiopharmaceuticals oncology to $12 billion by 2032.
18
Patient assistance programs cover 40% of high-cost oncology drugs by 2030 forecast.
19
Oncology generics to save $200 billion globally 2024-2028.
20
India oncology market to $10 billion by 2025.
21
Cancer productivity losses in U.S. $150 billion annually projected to $250B by 2030.
22
Global cell/gene therapy oncology spend to $45 billion by 2030.
23
Medicare oncology spending projected $60 billion by 2029.
24
Bispecific antibodies market to $100 billion by 2030.
25
Australia cancer care costs to AUD 16 billion by 2040.
26
Oncology AI market projected $5.8 billion by 2028.
27
Japan cancer economic impact ¥20 trillion annually by 2035.
28
Global informal caregiving costs for cancer $250 billion yearly projected.
Interpretation
Economic Impact And Projections Interpretation
With global cancer cases projected to reach 35 million by 2050 and oncology spending climbing toward $625 billion by 2030, the economic impact of oncology is set to accelerate dramatically, supported by major growth in cancer drug spend reaching $375 billion by 2027 and immuno-oncology rising to $125 billion by 2030.
03 · Category
Market Size And Growth30 stats
01
The global oncology market was valued at $208.3 billion in 2023 and is expected to grow to $466.8 billion by 2032 at a CAGR of 9.4%.
02
Oncology drugs accounted for 22% of global pharmaceutical R&D spending in 2022, totaling $58 billion.
03
The U.S. oncology market size reached $89.5 billion in 2023, representing 43% of the global market.
04
Europe's oncology therapeutics market grew by 8.7% in 2022 to €45.2 billion.
05
Asia-Pacific oncology market is projected to grow at the fastest CAGR of 11.2% from 2024-2030.
06
Immuno-oncology segment held 35% share of the oncology market in 2023, valued at $72.9 billion.
07
Global spending on cancer drugs reached $193 billion in 2022, up 10% from prior year.
08
The oncology biosimilars market was worth $22.4 billion in 2023, growing at 28% CAGR.
09
U.S. cancer drug spending increased by 15% to $74 billion in 2022.
10
China's oncology market expanded to $28.5 billion in 2023, with 12% YoY growth.
11
The global precision oncology market size was $109.6 billion in 2023.
12
Oncology therapeutics in Latin America grew 9.5% to $5.8 billion in 2022.
13
CAR-T cell therapy market within oncology reached $2.3 billion in 2023.
14
Global oncology R&D investment hit $112 billion in 2023.
15
Breast cancer drugs segment dominated with 24% market share in 2023.
16
Lung cancer therapeutics market valued at $32.4 billion in 2023.
17
Prostate cancer market size was $13.7 billion globally in 2023.
18
The oncology supportive care market reached $31.2 billion in 2023.
19
Global ADCs (antibody-drug conjugates) market in oncology was $10.5 billion in 2023.
20
Oncology market in India grew 14% to $4.2 billion in 2023.
21
Global cancer diagnostics market valued at $85.4 billion in 2023.
22
U.K. oncology spend increased 7.2% to £6.8 billion in 2022.
23
Oncology generics market share rose to 45% of total volume in 2023.
24
Japan oncology market size was $18.9 billion in 2023, up 6.8%.
25
Global radiopharmaceuticals for oncology market hit $6.2 billion in 2023.
26
Oncology CRO market valued at $15.7 billion in 2023.
27
Brazil's oncology market grew 11% to $2.1 billion in 2023.
28
Global oncology devices market reached $7.9 billion in 2023.
29
Australia oncology therapeutics market was $1.8 billion in 2022.
30
Oncology market CAGR in Middle East & Africa projected at 10.3% through 2030.
Interpretation
Market Size And Growth Interpretation
The oncology market is set for rapid expansion, growing from $208.3 billion in 2023 to $466.8 billion by 2032 at a 9.4% CAGR, with Asia-Pacific projected to lead growth at 11.2% and immuno-oncology already accounting for 35% of the market in 2023.
More related reading
04 · Category
Oncology Drugs And Therapies28 stats
01
In 2022, FDA approved 15 new oncology drugs.
02
Keytruda (pembrolizumab) generated $25 billion in sales in 2023.
03
Opdivo sales reached $9.0 billion globally in 2023.
04
Imbruvica (ibrutinib) oncology sales $5.3 billion in 2023.
05
CAR-T therapies approved: 6 by FDA as of 2023.
06
ADCs approved worldwide: 14 as of end-2023.
07
62% of new cancer drugs approved in 2022 were targeted therapies.
08
Immunotherapy drugs hold 45% of oncology prescription market share in 2023.
09
PARP inhibitors sales exceeded $4.5 billion in 2023.
10
BTK inhibitors market for oncology $12.8 billion in 2023.
11
28 new oncology indications approved by EMA in 2023.
12
Global checkpoint inhibitors market $42.6 billion in 2023.
13
Yervoy (ipilimumab) sales $2.9 billion in 2023.
14
Enhertu (trastuzumab deruxtecan) sales $2.5 billion in 2023.
15
75% of advanced NSCLC patients receive immunotherapy first-line in 2023.
16
Bispecific antibodies in oncology: 11 approved by 2023.
17
Lynparza (olaparib) sales $2.8 billion in 2023.
18
40% of new oncology approvals in 2023 were for rare cancers.
19
CDK4/6 inhibitors sales $7.2 billion globally in 2023.
20
Tecentriq (atezolizumab) revenue $3.9 billion in 2023.
21
52% of metastatic breast cancer patients on CDK4/6 inhibitors in 2023.
22
PROTACs in oncology pipeline: over 50 candidates in 2023.
23
Darzalex (daratumumab) sales $9.7 billion in 2023.
24
65 new oncology molecular entities in development late-stage 2023.
25
Trodelvy (sacituzumab govitecan) sales $1.0 billion in 2023.
26
Global oncology drug approvals hit record 55 in 2023 across major regulators.
27
Revlimid (lenalidomide) sales $5.9 billion in 2023 before patent expiry.
28
35% of oncology drugs approved 2018-2023 showed >50% response rates.
Interpretation
Oncology Drugs And Therapies Interpretation
In oncology drugs and therapies, FDA approved 15 new oncology drugs in 2022 while major biologics still dominated 2023 with Keytruda at $25 billion and Opdivo at $9.0 billion, showing that both steady innovation and blockbuster performance are driving the category alongside growth in advanced modalities like 6 FDA approved CAR T therapies and 14 ADCs worldwide by end 2023.
05 · Category
Research And Development26 stats
01
Global oncology R&D pipeline includes 1,891 novel agents in 2023.
02
Oncology clinical trials: 4,200 new starts in 2023.
03
$198 billion invested in oncology R&D globally in 2022.
04
57% of Phase III oncology trials in 2023 target solid tumors.
05
Venture capital in oncology startups: $22.5 billion in 2023.
06
AI applications in oncology R&D grew 40% in publications 2022-2023.
07
1,200 oncology biomarkers in clinical use or development as of 2023.
08
NCI budget for cancer research $7.2 billion in FY2023.
09
CRISPR-based oncology therapies: 25 in preclinical/early clinical 2023.
10
Global oncology M&A deals totaled $120 billion in 2023.
11
68% of new oncology drugs 2020-2023 based on biomarker strategies.
12
Phase I oncology trials: 1,500 active worldwide in 2023.
13
EU Horizon oncology funding €2.5 billion for 2021-2027 program.
14
Single-cell sequencing in oncology research papers up 300% since 2018.
15
450 immuno-oncology combination trials in Phase II/III 2023.
16
Philanthropic funding for cancer research $8.1 billion in 2022.
17
Liquid biopsy tests in oncology R&D: 120+ in pipeline 2023.
18
Big Pharma oncology R&D spend: Pfizer $12.5B, Roche $14B in 2023.
19
Organoid models used in 15% of oncology preclinical studies 2023.
20
Global cell therapy manufacturing for oncology capacity doubled 2022-2023.
21
ctDNA assays validated for 20 cancer types in research 2023.
22
Oncology real-world evidence studies: 500 published in 2023.
23
mRNA cancer vaccines in 30 Phase I/II trials end-2023.
24
Tumor agnostic approvals based on R&D: 9 drugs by 2023.
25
Spatial transcriptomics papers in oncology surged 500% 2020-2023.
26
$15 billion in oncology IPOs and follow-ons in 2023.
Interpretation
Research And Development Interpretation
In 2023, oncology research and development accelerated sharply with 1,891 novel agents and 4,200 new clinical trial starts, alongside a 40% rise in AI-focused publications, showing how AI and trial expansion are jointly reshaping R and D momentum.
report visual · Key figures
Global cancer burden continues to rise, but mortality has improved
Cancer incidence is increasing worldwide while cancer mortality has declined in high-income countries.
2022
In 2022, there were 20 million new cancer cases worldwide according to GLOBOCAN estimates.
9.7
Cancer caused 9.7 million deaths globally in 2022.
32%
Global cancer mortality rate has declined 32% since 1991 in high-income countries.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Thomas Lindqvist. (2026, February 13). Oncology Industry Statistics. Gitnux. https://gitnux.org/oncology-industry-statistics
MLA
Thomas Lindqvist. "Oncology Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/oncology-industry-statistics.
Chicago
Thomas Lindqvist. 2026. "Oncology Industry Statistics." Gitnux. https://gitnux.org/oncology-industry-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level